Gilead Sciences to expand cancer therapy portfolio with $21B deal for Immunomedics
Gilead Sciences will acquire biopharmaceutical company Immunomedics for $21 billion. The acquisition will expand Gilead’s portfolio of treatments for various types of cancer. Here are the details.
Read More